Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (Details Textual)

STOCKHOLDERS' EQUITY (Details Textual) (USD $)	1 Months Ended	0 Months Ended		12 Months Ended		1 Months Ended
STOCKHOLDERS' EQUITY (Details Textual) (USD $)	Aug. 20, 2014	Jun. 13, 2014	May 22, 2014	Dec. 31, 2014	Dec. 31, 2013	Feb. 28, 2013	Jun. 06, 2014	Feb. 20, 2014	Feb. 20, 2013	Aug. 14, 2014
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				6,604,096				275,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 10.00
Proceeds from Issuance or Sale of Equity	$ 13,475,832
Proceeds from (Repurchase of) Equity	11,877,143us-gaap_ProceedsFromRepurchaseOfEquity
Payments of Stock Issuance Costs	1,598,689us-gaap_PaymentsOfStockIssuanceCosts			518,822us-gaap_PaymentsOfStockIssuanceCosts	0us-gaap_PaymentsOfStockIssuanceCosts
Resale Of Shares Of Common Stock				200,000clrb_ResaleOfSharesOfCommonStock
Common Stock, Shares, Issued				7,562,762us-gaap_CommonStockSharesIssued	2,869,739us-gaap_CommonStockSharesIssued
Warrants Issued To Purchase Common Stock					275,000
Fair Value Of Warrants Classified As Derivative Liability Outstanding					5,720,000
Loss on issuance of derivative warrants				0	744,957
Change In Unrealized Gain Loss On Fair Value					2,365,000
Class of Warrant or Right, Outstanding				550,000
Unrealized Gain (Loss) on Derivatives				2,227,500us-gaap_UnrealizedGainLossOnDerivatives
Common Stock, Shares Authorized		20,000,000us-gaap_CommonStockSharesAuthorized		20,000,000us-gaap_CommonStockSharesAuthorized	20,000,000us-gaap_CommonStockSharesAuthorized		150,000,000us-gaap_CommonStockSharesAuthorized
Stockholders' Equity, Reverse Stock Split		1-for-20 reverse split	At the annual meeting of stockholders held on May 22, 2014, the Company’s stockholders approved an amendment to the certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue would be reduced from 150,000,000 to the greater of (A) 20,000,000 and (B) the number of shares equal to three (3) times the sum of the number of all shares of common stock outstanding and the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt.
February Offering One [Member]
Class of Warrant or Right [Line Items]
Common Stock, Shares, Issued									550,000
Warrants Issued To Purchase Common Stock									550,000
Warrants Exercise Price									$ 10.00
Gross Proceeds From Issuance Of Common Stock Warrants						5,500,000
Proceeds From Issuance Of Common Stock Warrants Net						4,975,153
February Offering Two [Member]
Class of Warrant or Right [Line Items]
Warrants Issued To Purchase Common Stock									275,000
Warrants Exercise Price									$ 10.00
February Offering [Member]
Class of Warrant or Right [Line Items]
Warrants Issued To Purchase Common Stock					38,500
Warrants Exercise Price					$ 12.50
Cash Fee Paid To Placement Agent					385,000
Warrants Expiration Date					Feb. 04, 2018
Maximum [Member]
Class of Warrant or Right [Line Items]
Percentage Of Liquidated Damages Per Month				5.00%
Minimum [Member]
Class of Warrant or Right [Line Items]
Percentage Of Liquidated Damages Per Month				1.50%
Underwriter [Member]
Class of Warrant or Right [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure	275,000
August 2014 Debenture [Member]
Class of Warrant or Right [Line Items]
Share Price	$ 3.76
Debt Instrument, Face Amount	4,000,000
Interest Payable	$ 172,435
August 2014 Underwritten Offering [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 3.75
Share Price										$ 3.75
Warrant [Member]
Class of Warrant or Right [Line Items]
Share Price	$ 0.01
Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues	3,583,333			3,583,333	550,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,833,333
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.68
Share Price	$ 3.75
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	6.40%
Common Stock [Member] \| Underwriter [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	96,988
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.6875
Common Stock [Member] \| August 2014 Debenture [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,109,690
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.68
Debt Conversion, Converted Instrument, Shares Issued	1,109,690